Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 3/20 | 0.44 |
| ▸ | XDH | P47989 | 1/20 | 0.44 |
| ▸ | SRC | P12931 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | NUDT1 | P36639 | 3/20 | 0.41 |
| ▸ | PRKCI | P41743 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | CCNC | P24863 | 1/20 | 0.38 |
| ▸ | CDK8 | P49336 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | DAO | P14920 | 1/20 | 0.38 |
| ▸ | ULK1 | O75385 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30731054 | 1.00 | ABL1 (0.44) | ABL1XDHSRCCYP1A2NUDT1 | |
| SCHEMBL30731078 | 0.86 | NUDT1 (0.48) | NUDT1GLAGAA | |
| SCHEMBL3603471 | 0.86 | NUDT1 (0.48) | NUDT1GLAGAA | |
| SCHEMBL30883103 | 0.83 | ABL1 (0.43) | ABL1XDHSRCCYP1A2NUDT1 | |
| SCHEMBL26620152 | 0.83 | ABL1 (0.43) | ABL1XDHSRCCYP1A2NUDT1 | |
| SCHEMBL30731002 | 0.83 | DAO (0.44) | NUDT1PRKCIDAO | |
| SCHEMBL22554070 | 0.83 | DAO (0.44) | NUDT1PRKCIDAO | |
| SCHEMBL30226495 | 0.82 | ABL1 (0.45) | ABL1SRCCYP1A2NUDT1PRKCI | |
| SCHEMBL7975640 | 0.82 | GLA (0.48) | ABL1SRCCYP1A2NUDT1DYRK1A | |
| SCHEMBL899166 | 0.82 | ABL1 (0.45) | ABL1SRCCYP1A2NUDT1PRKCI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240270757-A1 | SPIROCYCLIC COMPOUNDS | ASTRAZENECA AB (SE) | 2024-08-15 | — | — | US | disclosed |
| CN-117916241-A | Spiro compounds | 阿斯利康(瑞典)有限公司 | 2024-04-19 | — | — | CN | disclosed |
| US-11939344-B2 | Spirocyclic compounds | ASTRAZENECA AB (SE) | 2024-03-26 | — | — | US | disclosed |
| US-11919902-B2 | Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors | HIBERCELL, INC. (US) | 2024-03-05 | — | — | US | disclosed |
| CN-112088157-B | Aryl-bipyridylamine derivatives as phosphatidylinositol phosphokinase inhibitors | 拉文纳制药公司 | 2023-12-26 | — | — | CN | disclosed |
| US-20230357279-A1 | SPIROCYCLIC COMPOUNDS | ASTRAZENECA AB (SE) | 2023-11-09 | — | — | US | disclosed |
| US-20230357279-A1 | SPIROCYCLIC COMPOUNDS | ASTRAZENECA AB (SE) | 2023-11-09 | — | — | US | disclosed |
| US-20230357279-A1 | SPIROCYCLIC COMPOUNDS | ASTRAZENECA AB (SE) | 2023-11-09 | — | — | US | disclosed |
| CN-110483366-B | Indole compound and preparation method, pharmaceutical composition and application thereof | 中国医学科学院药物研究所 | 2022-09-16 | — | — | CN | disclosed |
| CN-112088157-A | Aryl-bipyridine amine derivatives as phosphoinositide kinase inhibitors | 拉文纳制药公司 | 2020-12-15 | — | — | CN | disclosed |
| EP-3728230-A1 | ARYL-BIPYRIDINE AMINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS | Ravenna Pharmaceuticals, Inc. (US) | 2020-10-28 | — | — | EP | disclosed |
| US-20200331913-A1 | ARYL-BIPYRIDINE AMINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS | HIBERCELL, INC. | 2020-10-22 | — | — | US | disclosed |
| US-20200331913-A1 | ARYL-BIPYRIDINE AMINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS | HIBERCELL, INC. | 2020-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200331913-A1 | ARYL-BIPYRIDINE AMINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS | PIP5K1A, PIP5K1B, PIP5K1C | ABL1 235/4885XDH 1762/4885SRC 757/4885 |
| US-20240270757-A1 | SPIROCYCLIC COMPOUNDS | PKD1, PKD2, CCNI | ABL1 1333/4885XDH 1507/4885SRC 1223/4885 |
| US-11919902-B2 | Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors | PIP5K1A, PIP5K1B, PIP5K1C | ABL1 235/4885XDH 1762/4885SRC 757/4885 |
| US-11939344-B2 | Spirocyclic compounds | PKD1, PKD2, NR5A1 | ABL1 2004/4885XDH 1787/4885SRC 1540/4885 |
| US-20230357279-A1 | SPIROCYCLIC COMPOUNDS | PKD1, PKD2, CCNI | ABL1 1333/4885XDH 1507/4885SRC 1223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.